It’s Time to Bring Dendritic Cell Therapy to Type 1 Diabetes

@inproceedings{Creusot2014ItsTT,
  title={It’s Time to Bring Dendritic Cell Therapy to Type 1 Diabetes},
  author={R{\'e}mi J Creusot and Nick Giannoukakis and Massimo M. Trucco and Michael J Clare-Salzler and C. Garrison Fathman},
  booktitle={Diabetes},
  year={2014}
}
Type 1 diabetes (T1D) is an autoimmune disease that results from a deficient induction or maintenance of tolerance to islet b-cell antigens, allowing the eventual T-cell–mediated destruction of insulin-producing b-cells within the pancreatic islets (1). Under homeostatic conditions, immune tolerance is established by various subsets of antigen-presenting cells (APCs) with toleranceinducing/maintaining (tolerogenic) functions and reinforced by other cells with suppressor and immunomodulatory… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 27 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 67 REFERENCES

Therapeutic potential of semi-mature dendritic cells for tolerance induction

MB Lutz
  • Front Immunol
  • 2012
VIEW 16 EXCERPTS
HIGHLY INFLUENTIAL

Detection of β cell death in diabetes using differentially methylated circulating DNA.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2011
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

A short pulse of IL-4 delivered by DCs electroporated with modified mRNA can both prevent and treat autoimmune diabetes in NOD mice.

  • Molecular therapy : the journal of the American Society of Gene Therapy
  • 2010
VIEW 18 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…